Skip to main content

IceCure Medical Ltd. (ICCM)

NASDAQ: ICCM · IEX Real-Time Price · USD
9.44 0.44 (4.89%)
Sep 22, 2021 11:50 AM EDT - Market open
Market Cap300.40M
Revenue (ttm)3.87M
Net Income (ttm)-3.73M
Shares Out31.82M
EPS (ttm)-0.12
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close9.00
Day's Range9.00 - 9.44
52-Week Range8.52 - 12.40
Price Targetn/a
Est. Earnings Daten/a

About ICCM

IceCure Medical is a commercial stage medical device company focusing on the research, development and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. In the United States our products are approved as a “single family” known as the “IceCure Family,” which includes the IceSense3, ProSense, and MultiSense (which has not been commercialized) cryoablation systems. Cryoablation is the process by which benign and malignant tumors are ablated (destroyed) through freezing such tumors whi...

IndustryMedical Care Facilities
IPO DatePending
CEOEyal Shamir
Stock ExchangeNASDAQ
Ticker SymbolICCM
Full Company Profile

Financial Performance

In 2020, ICCM's revenue was $3.87 million, an increase of 137.74% compared to the previous year's $1.63 million. Losses were -$3.73 million, -18.04% less than in 2019.

Financial Statements


IceCure Medical Shares to Begin Trading on Nasdaq Capital Market on August 26, 2021

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation...

3 weeks ago - PRNewswire

IceCure Medical IPO Registration Document (S-1)

IceCure Medical Ltd. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

IceCure Announces One-for-(8) Reverse Stock Split in Preparation for Nasdaq Listing

IceCure Medical Ltd. (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology...

1 month ago - PRNewswire